Prostate cancer as a model for tumour immunotherapy
/in Dendritic Cells, International Publications, Prostate CancerDendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters
/in Dendritic Cells, International Publications, Malignant MelanomaHuman myeloid dendritic cells for cancer therapy: does maturation matter?
/in Dendritic Cells, International PublicationsInduction of complete and molecular remissions in acute myeloid leukemia by Wilms‘ tumor 1 antigen-targeted dendritic cell vaccination
/in Acute Leukemia, Dendritic Cells, International PublicationsOptimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients
/in Dendritic Cells, International Publications, Multiple MyelomaAdvances in cellular therapy for the treatment of thyroid cancer
/in Dendritic Cells, International Publications, Thyroid CancerAnti-HER2 vaccines: new prospects for breast cancer therapy
/in Breast Cancer, Dendritic Cells, International PublicationsINGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect
/in Dendritic Cells, International Publications, SCLCDendritic cell vaccination as a treatment modality for mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer